nach oben

Osteoporosis International

Erschienen in:

01.02.2011 | Review

Osteoporosis in inflammatory joint diseases

verfasst von: C. Roux

Erschienen in: Osteoporosis International | Ausgabe 2/2011

Einloggen, um Zugang zu erhalten

Abstract

Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are two inflammatory joint diseases characterized by bone complications including osteoporosis. In RA, periarticular bone loss, bone erosions, and systemic osteoporosis are observed, with an increased risk of fractures. Determinants of fractures are underlying conditions (as RA has a female preponderance and an increased prevalence with age), severity of the disease, and use of glucocorticoids. However, bone loss can occur even in glucocorticoid-naive patients. Prospective data show that the optimal control of inflammation in RA is associated with decrease in structural damage and bone loss. RA illustrates the role of inflammation on bone resorption. In AS, osteoporosis is an early event and vertebral fracture risk is increased. Bone loss is related mainly to inflammation, as the disease can occur in young male adult populations, and glucocorticoids are not used in this disease. However, AS is characterized by progressive stiffness and ankylosis of the spine and illustrates also the potential role of inflammation on local bone formation.

van Staa TP, Geusens P, Bijlsma WJ, Leufkens HGM, Cooper C (2006) Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 54:3104–3112PubMedCrossRef

Orstavik RE, Haugeberg G, Uhlig T, Mowinckel P, Falch JA, Halse JI et al (2004) Self reported non-vertebral fractures in rheumatoid arthritis and population based controls: incidence and relationship with bone mineral density and clinical variables. Ann Rheum Dis 63:177–182PubMedCrossRef

Huusko TM, Korpela M, Karppi P, Avikainen V, Kautiainen H, Sulkava R (2001) Threefold increased risk of hip fractures with rheumatoid arthritis in Central Finland. Ann Rheum Dis 60:521–522PubMedCrossRef

Hooyman JR, Melton LJ, Nelson AM, O’Fallon WM, Riggs BL (1984) Fractures after rheumatoid arthritis. Arthritis Rheum 27:1353–1361PubMedCrossRef

Orstavik RE, Haugeberg G, Mowinckel P, Hoiseth A, Uhlig T, Falch JA, Halse JI, Mc Closkey E, Kvien TK (2004) Vertebral deformities in rheumatoid arthritis. Arch Intern Med 164:420–425PubMedCrossRef

de Nijs RNJ, Jacobs JWG, Bijlsma JWJ, Lems WF, Laan RFJM, Houben HHM, ter Borg EJ, Huisman AM, Bruyn GAW, van Oijen PLM, Westgeest AAA, Algra A, Hofman DM, on behalf of the Osteoporosis Working Group of the Dutch Society for Rheumatology (2001) Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritis. Rheumatology 40:1375–1383PubMedCrossRef

Spector TD, Hall GM, Mc Closkey EV, Kanis JA (1993) Risk of vertebral fracture in women with rheumatoid arthritis. BMJ 306:558PubMedCrossRef

Pell NF, Moore DJ, Barrington NA, Bax DE, Eastell R (1995) Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann Rheum Dis 54:801–806CrossRef

Orstavik RE, Haugeberg G, Uhlig T, Mowinckel P, Falch JA, Halse JI, Kvien T (2005) Incidence of vertebral deformities in 255 female rheumatoid arthritis patients measured by morphometric X-ray absorptiometry. Osteoporos Int 16:35–42PubMedCrossRef

10.

Lodder MC, Haugeberg G, Lems WF, Uhlig T, Orstavik RE, Kostense PJ et al (2003) Radiographic damage associated with low bone mineral density and vertebral deformities in rheumatoid arthritis: the Oslo–Truro–Amsterdam (OSTRA) collaborative study. Arthritis Rheum 49:209–215PubMedCrossRef

11.

Lems WF, Jahangier ZN, Jacobs JWG, Bijlsma JWJ (1995) Vertebral fractures in patients with rheumatoid arthritis treated with corticosteroids. Clin Exp Rheumatol 13:293–297PubMed

12.

Ursum J, Britsemmer K, van Schaardenburg D, Lips PTA, Dijkmans BAC, Lems W (2009) High prevalence of vertebral deformities in elderly patients with early rheumatoid arthritis. Ann Rheum Dis 68:1512–1513PubMedCrossRef

13.

Sinigaglia L, Nervetti A, Mela Q, Bianchi G, Del Puente A, Di Munno O, Frediano B, Cantatore F, Pellerito R, Bartolone S, La Montagna G, Adami S (2000) High prevalence of vertebral deformities in elderly patients with early rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. J Rheumatol 27:2582–2589PubMed

14.

Smulders E, Schreven C, Weerdesteyn V et al (2009) Fall incidence and fall risk factors in people with rheumatoid arthritis. Ann Rheum Dis 68:1795–1796PubMedCrossRef

15.

Hayashibara M, Hagino H, Katagiri H, Okano T, Okada J, Teshima R (2010) Incidence and risk factors of falling in ambulatory patients with rheumatoid arthritis: a prospective 1-year study. Osteoporos Int. doi:10.1007/s00198-009-1150-4

16.

Jamison M, Neuberger GB, Miller PA (2003) Correlates of falls and fear of falling among adults with rheumatoid arthritis. Arthritis Rheum 49:673–680PubMedCrossRef

17.

Roubenoff R, Roubenoff RA, Cannon JG, Kehayias JJ, Zhuang H, Dawson-Hughes B et al (1994) Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest 93:2379–2386PubMedCrossRef

18.

Giles JT, Ling SM, Ferrucci L, Bartlett SJ, Andersen RE, Towns M, Muller D, Fontaine KR, Bathon JM (2008) Abnormal body composition phenotypes in older rheumatoid arthritis patients: association with disease characteristics and pharmacotherapies. Arthritis Rheum 59:807–815PubMedCrossRef

19.

Matschke V, Murphy P, Lemmey AB, Maddison PJ, Thom JM (2010) Muscle quality, architecture, and activation in cachetic patients with rheumatoid arthritis. J Rheumatol 37:282–284PubMedCrossRef

20.

Marcora SM, Chester KR, Mittal G, Lemmey AB, Maddison PJ (2006) Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr 84:1463–1472PubMed

21.

Marcora SM, Lemmey AB, Maddison PJ (2005) Can progressive resistance training reverse cachexia in patients with rheumatoid arthritis? Results of a pilot study. J Rheumatol 32:1031–1039PubMed

22.

Orstavik RE, Haugeberg G, Uhlig T, Falch JA, Halse JI, Hoiseth A, Lilleas F, Kvien TK (2003) Vertebral deformities in 229 female patients with rheumatoid arthritis: associations with clinical variables and bone mineral density. Arthritis Rheum 3:355–360CrossRef

23.

Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK (2000) Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis. Arthritis Rheum 43:522–530PubMedCrossRef

24.

Martin JC, Munro R, Campbell MK, Reid DM (1997) Effects of disease and corticosteroids on appendicular bone mass in postmenopausal women with rheumatoid arthritis: comparison with axial measurements. Br J Rheumatol 36:43–49PubMedCrossRef

25.

Hall GM, Spector TD, Griffin AJ, Jawad ASM, Hall ML, Doyle DV (1993) The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women. Arthritis Rheum 36:1510–1516PubMedCrossRef

26.

Sambrook PN, Eisman JA, Champion GD, Yeates MG, Pocock NA, Eberl S (1987) Determinants of axial bone loss in rheumatoid arthritis. Arthritis Rheum 30:721–728PubMedCrossRef

27.

Kroger H, Honkanen R, Saarikoski S, Alhava E (1994) Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis—a population based study. Ann Rheum Dis 53:18–23PubMedCrossRef

28.

Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK (2000) Reduced bone mineral density in male rheumatoid arthritis patients. Arthritis Rheum 43:2776–2784PubMedCrossRef

29.

Gough AK, Lilley J, Eyre S, Holder RL, Emery P (1994) Generalised bone loss in patients with early rheumatoid arthritis. Lancet 344:23–27PubMedCrossRef

30.

Lodder MC, de Jong Z, Kostense PJ, Molenaar ETH, Staal K, Voskuyl AE, Hazes JMW, Dijkmans BAC, Lems WF (2004) Bone mineral density in patients with rheumatoid arthritis: relation between disease severity and low bone mineral density. Ann Rheum Dis 63:1576–1580PubMedCrossRef

31.

Güler-Yüksel M, Bijsterbosch J, Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Ronday HK, Peeters AJ, de Jonge-Bok JM, Breedveld FC, Dijkmans BAC, Allaart CF, Lems WF (2007) Bone mineral density in patients with recently diagnosed, active rheumatoid arthritis. Ann Rheum Dis 66:1508–1512PubMedCrossRef

32.

Forslind K, Keller C, Svensson B, Hafstrom I (2003) Reduced bone mineral density in early rheumatoid arthritis is associated with radiological joint damage at baseline and after 2 years in women. J Rheumatol 30:2590–2596PubMed

33.

Kroot EJJA, Nieuwenhuizen MG, Waal Malefijt MC de, Riel PLCM van, Pasker-de Jong PCM van, Laan RFJM (2001) Change in bone mineral density in patients with rheumatoid arthritis during the first decade of the disease. Arthritis Rheum 44:1254–1260PubMedCrossRef

34.

Chopin F, Garnéro P, le Henanff A, Debiais F, Daragon A, Roux C, Sany J, Wendling D, Zarnitsky C, Ravaud P, Thomas T (2008) Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis 67:353–357PubMedCrossRef

35.

Haugeberg G, Conaghan PG, Quinn M, Emery P (2009) Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study. Ann Rheum Dis 68:1898–1901PubMedCrossRef

36.

Vis M, Havaardsholm EA, Haugeberg G, Uhlig T, Voskuyl AE, van de Stadt RJ, Dijkmans BAC, Woolf AD, Kvien TK, Lems WF (2006) Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 65:1495–1499PubMedCrossRef

37.

Wijbrandts CA, Klaasen R, Dijkgraaf MGW, Gerlag DM, van Eck-Smit BLF, Tak PP (2009) Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. Ann Rheum Dis 68:373–376PubMedCrossRef

38.

Haugeberg G, Strand A, Kvien TK et al (2005) Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo controlled trial. Arch Intern Med 165:1293–1297PubMedCrossRef

39.

Peel NFA, Spittlehouse AJ, Bax DE, Eastell R (1994) Bone mineral density of the hand in rheumatoid arthritis. Arthritis Rheum 5:983–991CrossRef

40.

Deodhar AA, Brabyn J, Pande I, Scott DL, Woolf AD (2003) Hand bone densitometry in rheumatoid arthritis, a five year longitudinal study: an outcome measure and a prognostic marker. Ann Rheum Dis 62:767–770PubMedCrossRef

41.

Haugeberg G, Green MJ, Quinn MA, Marzo-Ortega H, Proudman S, Karim Z, Wakefield RJ, Conaghan PG, Stewart S, Emery P (2006) Hand bone loss in early undifferentiated arthritis: evaluating bone mineral density loss before the development of rheumatoid arthritis. Ann Rheum Dis 65:736–740PubMedCrossRef

42.

Jensen T, Klarlund M, Hansen M, Jensen KE, Podenphant J, Hansen TM, Skjodt H, Hydstrup L (2004) Bone loss unclassified polyarthritis and early rheumatoid arthritis is better detected by digital X-ray radiogrammetry than dual X-ray absorptiometry: relationship with disease activity and radiographic outcome. Ann Rheum Dis 63:15–22PubMedCrossRef

43.

Bottcher J, Pfeil A, Rosholm A, Petrovitch A, Seidl BE, Malich A, Schafer ML, Kramer A, Mentzel HJ, Lehmann G et al (2005) Digital X-ray radiogrammetry combined with semiautomated analysis of joint space widths as a new diagnostic approach in rheumatoid arthritis: a cross-sectional and longitudinal study. Arthritis Rheum 52:3850–3859PubMedCrossRef

44.

Haugeberg G, Green MJ, Conaghan PG, Quinn M, Wakefield R, Proudman SM, Stewart S, Hensor E, Emery P (2007) Hand bone densitometry: a more sensitive standard for the assessment of early bone damage in rheumatoid arthritis. Ann Rheum Dis 66:1513–1517PubMedCrossRef

45.

Hoff M, Haugeberg G, Kvien TK (2007) Hand bone loss as an outcome measure in established rheumatoid arthritis: 2-year observational study comparing cortical and total bone loss. Arthritis Res Ther 9:1–8CrossRef

46.

Alenfeld FE, Diessel E, Brezger M, Sieper J, Felsenberg D, Braun J (2000) Detailed analyses in periarticular osteoporosis in rheumatoid arthritis. Osteoporos Int 11:400–407PubMedCrossRef

47.

Lindqvist E, Jonsson K, Saxne T, Eberhardt K (2003) Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis. Ann Rheum Dis 62:611–616PubMedCrossRef

48.

Hoff M, Haugeberg G, Odegard S, Syversen S, Landewé R, van der Heijde D, Kvien TK (2009) Cortical hand bone loss after 1 year in early rheumatoid arthritis predicts radiographic hand joint damage at 5-year and 10-year follow-up. Ann Rheum Dis 68:324–329PubMedCrossRef

49.

Güler-Yüksel M, Allaart CF, Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, van Groenendael JHLM, Mallée C, de Bois MHW, Breedveld FC, Dijkmans BAC, Lems WF (2009) Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 68:330–336PubMedCrossRef

50.

Boyesen P, Hoff M, Odegard S, Haugeberg G, Syversen SW, Gaarder PI, Okkenhaug C, Kvien TK (2009) Antibodies to cyclic citrillunated protein and ESR predict hand bone loss in patients with RA of short duration. Arthritis Res Ther 11:R103PubMedCrossRef

51.

Stach CM, Bäuerle M, Englbrecht M, Kronke G, Engelke K, Manger B, Schett G (2010) Periarticular bone structure in rheumatoid arthritis patients and healthy individuals assessed by high-resolution computed tomography. Arthritis Rheum 62:330–339PubMed

52.

Molenaar ET, Voskuyl AE, Dinant HJ, Bezemer PD, Boers M, Dijkmans BA (2004) Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum 50:36–42PubMedCrossRef

53.

Schett G, Kiechl S, Weger S, Pederiva A, Mayr A, Petrangeli M, Oberhollenzer F, Lorenzini R, Redlich K, Axmann R, Zwerina J, Willeit J (2006) High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study. Arch Intern Med 166:2495–2501PubMedCrossRef

54.

Ding C, Parameswaran V, Udayan R, Burgess J, Jones G (2008) Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal study. J Clin Endocrinol Metab 93:1952–1958PubMedCrossRef

55.

Cauley JA, Danielson ME, Boudreau RM, Forrest KYZ, Zmuda J, Pahor M, Tylavsky FA, Cummings SR, Harris TB, Newman AB, for the Health ABC study (2007) Inflammatory markers and incident fracture risk in older men and women: the Health Aging and Body Composition Study. J Bone Miner Res 22:1088–1095PubMedCrossRef

56.

Charactcharoenwitthaya N, Khosla S, Atkinson EJ, McCready LK, Riggs BL (2007) Effect of blockade of TNF-α and interleukin-1 action on bone resorption in early postmenopausal women. J Bone Miner Res 22:724–729CrossRef

57.

Cortet B, Flipo RM, Pigny P, Duquesnoy B, Boersma A, Marchandise X, Delcambre B (1998) Is bone turnover a determinant of bone mass in rheumatoid arthritis? J Rheumatol 25:2339–2344PubMed

58.

Gough A, Sambrook P, Devlin J, Huissoon A, Njeh C, Robbins S, Nguyen T, Emery P (1998) Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol 25:1282–1289PubMed

59.

Garnéro P, Landewe R, Boers M, Verhoeven A, van der Linden S, Christgau S, van der Heijde D, Boonen A, Geusens P (2002) Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis. The Cobra Study. Arthritis Rheum 46:2847–2856PubMedCrossRef

60.

Geusens PP, Landewé RBM, Garnéro P, Chen D, Dunstan CR, Lems WF, Stinissen P, van der Heijde DMFM, van der Linden S, Boers M (2006) The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. Arthritis Rheum 54:1772–1777PubMedCrossRef

61.

Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, Steiner G, Smolen JS, Wagner EF, Schett G (2002) Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest 110:1419–1427PubMed

62.

Jimenez-Boj E, Redlich K, Türk B, Hanslik-Schnabel H, Wanivenhaus A, Chott A, Smolen JS, Schett G (2005) Interaction between synovial inflammatory tissue and bone marrow in rheumatoid arthritis. J Immunol 175:2579–2588PubMed

63.

Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S et al (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoproteogerin ligand. Nature 402:304–309PubMedCrossRef

64.

Zaiss MM, Axmann R, Zwerina J, Polzer K, Gückel E, Skapenko A, Schulze-Koops H, Horwood N, Cope A, Schett G (2007) Treg cells suppress ostoclast formation. A new link between the immune system and bone. Arthritis Rheum 56:4104–4112PubMedCrossRef

65.

Axmann R, Herman S, Zaiss M, Franz S, Polzer K, Zwerina J, Hermann M, Smolen J, Schett G (2008) CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis 67:1603–1609PubMedCrossRef

66.

Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y, Cua DJ (2006) Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203:2673–2682PubMedCrossRef

67.

Pettit AR, Walsh NC, Manning C, Goldring SR, Gravallese EM (2006) RANKL protein is expressed at the pannus–bone interface at sites of articular bone erosion in rheumatoid arthritis. Rheumatology 45:1068–1076PubMedCrossRef

68.

Li C, Wei XQ, Evans B, Jiang W, Aeschlimann D (2008) IL-23 promotes osteoclast formation by up-regulation of receptor activator of NF-kb (RANK) expression in myeloid precursor cells. Eur J Immunol 38:2845–2854CrossRef

69.

Herman S, Mueller R, Kronke G, Zwerina J, Redlich K, Hueber A, Gelse H, Neumann E, Mueller-Ladner U, Schett G (2008) OSCAR, a key co-stimulation molecule for osteoclasts, is induced in patients with rheumatoid arthritis. Arthritis Rheum 58:3041–3050PubMedCrossRef

70.

Schett G, Redlich K, Hayer S et al (2003) Osteoproteogerin protects against generalized bon loss in tumor necrosis factor-transgenic mice. Arthritis Rheum 48:2042–2051PubMedCrossRef

71.

Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL (2000) TNFα induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligang. J Clin Invest 106:1481–1488PubMedCrossRef

72.

Polzer K, Joosten L, Gasser J, Distler JH, Ruiz G, Baum W, Redlich K, Bobacz K, Smolen JS, van den Berg W, Schett G, Zwerina J (2010) Interleudin-1 is essential for systemic inflammatory bone loss. Ann Rheum Dis 69:284–290PubMedCrossRef

73.

Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C, van der Heide D, Landewé R, Lacey D, Richard WG, Schett G (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13:156–163PubMedCrossRef

74.

Walsh NC, Reinwald S, Manning CA, Condon KW, Iwata K, Burr DB, Gravallese EM (2009) Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res 24:1572–1585PubMedCrossRef

75.

Axmann R, Böhm C, Krönke G, Zwerina J, Smolen J, Schett G (2009) Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. Arthritis Rheum 60:2747–2756PubMedCrossRef

76.

Saidenberg-Kermanac’h N, Corrado A, Lemeiter D, de Vernejoul MC, Boissier MC, Cohen-Solal M (2004) TNF-α antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. Bone 35:1200–1207PubMedCrossRef

77.

Stolina M, Schett G, Dwyer D, Vonderfecht S, Middleton S, Duryea D, Pacheco E, Van G, Bolon B, Feige U, Zack D, Kostenuik P (2009) RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFα or anti-IL-1 therapies. Arthritis Res Ther 11:11–15CrossRef

78.

Haynes D, Crotti T, Weedon H, Slavotinek J, Au V, Coleman M, Roberts-Thomson PJ, Ahern M, Smith MD (2008) Modulation of RANKL and osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis in response to disease-modifying antirheumatic drug treatment and correlation with radiologic outcome. Arthritis Rheum 59:911–920PubMedCrossRef

79.

Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, van der Heijde D, Zhou L, Tsuji W, Newmark R, on behalf of the Denosumab Rheumatoid Arthritis Study Group (2008) Denosumab treatment effects on strutural damage, bone mineral density, and bone turnover in rheumatoid arthritis. Arthritis Rheum 58:1299–1309PubMedCrossRef

80.

Will R, Palmer R, Bhalla AK, Ring F, Calin A (1989) Osteoporosis in early ankylosing spondylitis. A primary pathological event? Lancet ii:1483–1485CrossRef

81.

Maillefert JF, Aho S, El Maghraoui A, Dougados M, Roux C (2001) Changes in bone density in patients with ankylosing spondylitis: a 2 year follow-up study. Osteoporos Int 12:605–609PubMedCrossRef

82.

Geusens P, Vosse D, van der Heijde DM et al (2001) High prevalence of thoracic vertebral deformities and discal wedging in ankylosing spondylitis patients with hyperkyphosis. J Rheumatol 28:1856–1861PubMed

83.

Raltson SH, Urquhart GDK, Bzeski M, Sturrock RD (1990) Prevalence of vertebral compression fractures due to osteoporosis in ankylosing spondylitis. Br Med J 300:563–565CrossRef

84.

Cooper C, Carbone L, Michet CJ, Atkinson EJ, O’Fallon WM, Melton LJ (1994) Fracture risk in patients with ankylosing spondylitis: a population based study. J Rheumatol 21:1877–1882PubMed

85.

Donnelly S, Doyle DV, Denton A, Rolfe J, McCloskey EV, Spector TD (1994) Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis. Ann Rheum Dis 53:117–121PubMedCrossRef

86.

Mitra D, Elvins DM, Speden DJ et al (2000) The prevalence of vertebral fractures in mild ankylosing spondylitis and their relationship to bone mineral density. Rheumatology 39:85–89PubMedCrossRef

87.

Vosse D, Feidtkeller E, Erlendsson J et al (2004) Clinical vertebral fractures in patients with ankylosing spondylitis. J Rheumatol 31:1981–1985PubMed

88.

Feldtkeller E, Vosse D, Geusens P, van der Linden S (2006) Prevalence and annual incidence of vertebral fractures in patients with ankylosing spondylitis. Rheumatol Int 26:234–239PubMedCrossRef

89.

Vosse D, Landewé R, van der Heijde D, van der Linden S, van Staa TP, Geusens P (2009) Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case–control study. Ann Rheum Dis 68:1839–1842PubMedCrossRef

90.

Devogelaer JP, Maldague B, Malghem J, Nagant de Deuxchaisnes C (1992) Appendicular and vertebral bone mass in ankylosing spondylitis. Arthritis Rheum 35:1062–1067PubMedCrossRef

91.

Jun JB, Joo KB, Her MY, Kim TH, Bae SC, Yoo DH, Kim SK (2006) Femoral bone mineral density is associated with vertebral fractures in patients with ankylosing spondylitis: a cross-sectional study. J Rheumatol 33:1637–1641PubMed

92.

El Maghraoui A, Borderie D, Edouard R, Roux C, Dougados M (1999) Osteoporosis, body composition and bone turnover in ankylosing spondylitis. J Rheumatol 26:2205–2209PubMed

93.

Toussirot E, Michel F, Wendling D (2001) Bone density, ultrasound measurements and body composition in early ankylosing spondylitis. Rheumatology 40:882–888PubMedCrossRef

94.

Ghozlani I, Ghazi M, Nouijai A, Mounach A, Rezqi A, Achemlal L, Bezza A, Maghraoui A El (2009) Prevalence and risk factors of osteoporosis and vertebral fractures in patients with ankylosing spondylitis. Bone 44:772–776PubMedCrossRef

95.

Karberg K, Zochling J, Sieper J, Felsenberg D, Braun J (2005) Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol 32:1290–1298PubMed

96.

Obermayer-Pietsch BM, Lange U, Tauber G et al (2003) Vitamin D receptor initiation codon polymorphism, bone density and inflammatory activity of patients with ankylosing spondylitis. Osteoporos Int 14:995–1000PubMedCrossRef

97.

Gratacos J, Collado A, Pons F, Osaba M, Sammarti R, Roqué M et al (1999) Significant loss of bone mass in patients with early, active ankylosing spondylitis. A follow-up study. Arthritis Rheum 42:2319–2324PubMedCrossRef

98.

Visvanathan S, van der Heijde D, Deodhar A, Wagner C, Baker DG, Han J, Braun J (2009) Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis 68:175–182PubMedCrossRef

99.

Allali F, Breban M, Porcher R, Maillefert JF, Dougados M, Roux C (2003) Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha. Ann Rheum Dis 62:347–349PubMedCrossRef

100.

Briot K, Gossec L, Kolta S, Dougados M, Roux C (2008) Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-α treatment. J Rheumatol 35:855–861PubMed

101.

Vosse D, Landewé R, Garnéro P, van der Heijde D, van der Linden S, Geusens P (2008) Association of markers of bone – and cartilage – degradation with radiological changes at baseline and after 2 years follow-up in patients with ankylosing spondylitis. Rheumatology 1-4

102.

MacDonald AG, Birkinshaw G, Durham B, Bucknall RC, Fraser WD (1997) Biomedical markers of bone turnover in seronegative spondylarthropathy: relationship to disease activity. Br J Rheum 36:50–53CrossRef

103.

Stupphann D, Ranner M, Krenbeck D et al (2008) Intracellular and surface RANK L are differentially regulated in patients with ankylosing spondylitis. Rheumatol Int 28:987–993PubMedCrossRef

104.

Rauner M, Stupphann D, Haas M, Fert I, Glatigny S, Sipos W, Bréban M, Pietschmann P (2009) The HLA-B27 transgenic rat, a model of spondyloarthritis, has decreased bone mineral density and increased RANKL to osteoprotegerin mRNA ratio. J Rheumatol 36:120–126PubMed

105.

Maksymowych WP, Chiowchanwisawakit P, Clare T, Pedersen SJ, Ostergaard M, Lambert RGW (2009) Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis. Arthritis Rheum 60:93–102PubMedCrossRef

106.

Lories RJU, Derese I, Luyten FP (2005) Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 115:1571–1579PubMedCrossRef

107.

Lories RJ, Derese I, Ceuppens JL, Luyten FP (2003) Bone morphogenetic proteins 2 and 6, expressed in arthritic synovium, are regulated by pro inflammatory cytokines, and differentially modulate fibroblast-like synoviocyte apoptosis. Arthritis Rheum 48:2807–2818PubMedCrossRef

108.

Appel H, Ruiz-Heiland G, Listing J, Zwerina J, Herrmann M, Mueller R, Haibel H, Baraliakos X, Hempfing A, Rudwaleit M, Sieper J, Schett G (2009) Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 60:3257–3262PubMedCrossRef

109.

Schett G, Stolina M, Dwyer D, Zack D, Uderhardt S, Krönke G, Kostenuik P, Feige U (2009) Tumor necrosis factor α and RANKL blockade cannot halt bony spur formation in experimental inflammatory arthritis. Arthritis Rheum 60:2644–2654PubMedCrossRef

110.

Uderhardt S, Diarra D, Katzenbeisser J, David JP, Zwerina J, Richards WG, Krönke G, Schett G (2010) Blockade of dickkopf-1 induces fusion of sacroiliac joints. Ann Rheum Dis 69:592–597PubMedCrossRef

111.

Daoussis D, Liossis SNC, Solomou EE, Tsanaktsi A, Bounia K, Karampetsou M, Yiannopoulos G, Andonopoulos AP (2010) Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum 62:150–158PubMedCrossRef

112.

Mc Gonagle D, Wakefield RJ, Tan AL, D’agostino MA, Toumi H, Hayashi K, Emery P, Benjamin M (2008) Distinct topography of erosion and new bone formation in Achilles tendon enthesitis. Implications for understanding the link between inflammation and bone formation in spondylarthritis. Arthritis Rheum 58:2694–2699CrossRef

113.

Lories RJU, Derese I, De Bari C, Luyten FP (2007) Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis Rheum 56:489–497PubMedCrossRef

114.

Iwasawa T, Iwasaki K, Sawada T, Okada A, Ueyama K, Motomura S, Harata S, Inoue I, Toh S, Furukawa KI (2006) Pathophysiological role of endothelin in ectopic ossification of human spinal ligaments induced by mechanical stress. Calcif Tissue Int 79:422–430PubMedCrossRef

115.

Clines GA, Mohammad KS, Bao Y, Stephens OW, Suva LJ, Shaughnessy JD, Fox JW, Chirgwin JM, Guise TA (2007) Dickkopf homolog 1 mediates endothelin-1 stimulated new bone formation. Mol Endocrinol 21:486–498PubMedCrossRef

Titel: Osteoporosis in inflammatory joint diseases
verfasst von: C. Roux
Publikationsdatum: 01.02.2011
Verlag: Springer-Verlag
Erschienen in: Osteoporosis International / Ausgabe 2/2011
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-010-1319-x

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen.
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

25.04.2024 | Gonarthrose | Nachrichten

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Osteoporosis in inflammatory joint diseases

Abstract

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Arthroskopie kann Knieprothese nicht hinauszögern

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Ärztliche Empathie hilft gegen Rückenschmerzen

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Update Orthopädie und Unfallchirurgie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2011

Epidemiology of hip fractures in Austria: evidence for a change in the secular trend

Preventing osteoporosis with a tissue selective estrogen complex (TSEC) containing bazedoxifene/conjugated estrogens (BZA/CE)

Prevalence and risk factors of radiographic vertebral fracture in Brazilian community-dwelling elderly

Oleuropein enhances osteoblastogenesis and inhibits adipogenesis: the effect on differentiation in stem cells derived from bone marrow

Socioeconomic and living conditions are determinants of hip fracture incidence and age occurrence among community-dwelling elderly

Hip fracture risk in older US adults by treatment eligibility status based on new National Osteoporosis Foundation guidance

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Arthroskopie kann Knieprothese nicht hinauszögern

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Ärztliche Empathie hilft gegen Rückenschmerzen

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Update Orthopädie und Unfallchirurgie